Peroxisome proliferator-activated receptor γ coactivator 1β (PGC-1β) improves skeletal muscle mitochondrial function and insulin sensitivity by Handschin, C.
Institutional Repository of the University of Basel 
University Library
Schoenbeinstrasse 18-20
CH-4056 Basel, Switzerland 
http://edoc.unibas.ch/
Year: 2011 
Peroxisome proliferator-activated receptor γ coactivator 1β (PGC-1β) 
improves skeletal muscle mitochondrial function and insulin 
sensitivity 
Handschin, C. 
Posted at edoc, University of Basel 
Official URL: http://edoc.unibas.ch/dok/A6005408 
Originally published as: 
Handschin, C.. (2011) Peroxisome proliferator-activated receptor γ coactivator 1β (PGC-1β) improves 
skeletal muscle mitochondrial function and insulin sensitivity. Diabetologia, Vol. 54, no. 6. S. 1270-1272. 
PGC-1 improves skeletal muscle mitochondrial function and insulin sensitivity 
Christoph Handschin 
Biozentrum, Div. of Pharmacology/Neurobiology, University of Basel, 
Klingelbergstrasse 50/70, CH-4056 Basel, Switzerland 
Published in Diabetologia. 2011 Jun;54(6):1270-2. PMID: 21461634. doi: 
10.1007/s00125-011-2135-3 
Copyright © Springer; Diabetologia 
PGC-1 improves skeletal muscle mitochondrial function and insulin sensitivity 
 
Christoph Handschin 
 
Biozentrum, Div. of Pharmacology/Neurobiology, University of Basel, 
Klingelbergstrasse 50/70, CH-4056 Basel, Switzerland 
 
Correspondence to: christoph.handschin@unibas.ch 
 
Abstract 
 
The peroxisome proliferator-activated receptor  coactivator 1 (PGC-1) proteins are 
key regulators of cellular energy homeostasis in a number of oxidative tissues, 
including skeletal muscle. While the regulation and function of PGC-1 seems central 
to muscle fiber plasticity in endurance exercise, the role of PGC-1 in this tissue is 
less clear. Wright and coworkers now provide evidence for a protective effect of 
moderately elevated PGC-1 in electroporated rat skeletal muscle against high fat 
diet-induced insulin resistance at least in part by promoting the oxidation of long 
chain acyl-CoA entities and the elimination of reactive oxygen species. These data 
provide important insights into the biological role of PGC-1 in skeletal muscle and 
imply novel therapeutic avenues for improving peripheral insulin sensitivity. 
 
 
Main text 
 
Adequate oxidative capacity and mitochondrial function of skeletal muscle are crucial 
for maintaining systemic glucose and insulin levels and accordingly, the regulation of 
these processes is tightly controlled. In recent years, the three members of the 
peroxisome proliferator-activated receptor  coactivator 1 (PGC-1) family of 
transcriptional coactivators have emerged as central regulators of energy homeostasis 
in muscle and other tissues. PGC-1 gene expression, protein levels and protein 
activity are affected by almost all of the signaling pathways that are activated in the 
contracting muscle fibers [1]. In turn, PGC-1 controls the adaptive changes elicited 
by endurance training [1]. In contrast to the more detailed informations about PGC-
1, much less is known about PGC-1 and the PGC-1-related coactivator (PRC). 
While the relative levels of physical activity is the dominant regulator of PGC-1 
gene expression in skeletal muscle, transcriptional control of PGC-1 seems less 
coherent and different effects of exercise, denervation, dietary restriction, bariatric 
surgery, obesity or insulin stimulation on muscle PGC-1 transcript levels have been 
described, some with conflicting results in different experimental settings 
(summarized in refs. [1-4]). The elegant study by Wright and colleagues published in 
this issue of Diabetologia now sheds more light on the important role of PGC-1 in 
muscle physiology [2]. Wright et al. overexpressed PGC-1 in electroporated tibialis 
cranialis and extensor digitorum longus muscles of low fat- or high fat-fed rats. 
Despite the very moderate increase in PGC-1 levels, a significant elevation in 
mitochondrial oxidative capacity, reactive oxidative species detoxification and lipid 
metabolism ensued. Importantly though, ectopic expression of PGC-1 in the high 
fat-fed rats also boosted insulin sensitivity. While a causal link between reduced 
insulin resistance and the observed induction of long chain acyl-CoA metabolism and 
antioxidant defense by PGC-1 was not examined, these long chain acyl-CoA and 
reactive oxygen species are strong candidate entities to contribute to the development 
of muscle insulin resistance [5]. 
 
A dysregulation of PGC-1 and PGC-1 gene expression levels has been found in 
skeletal muscle of prediabetic and type 2 diabetic individuals, at least in some 
populations [6, 7]. Studies in skeletal muscle-specific knockout mice for PGC-1 and 
PGC-1 alone failed to show a direct involvement of genetic ablation of the 
individual coactivators in the etiology of insulin resistance in this tissue [8-10]. The 
consequence of a PGC-1/PGC-1 muscle-specific double knockout approach 
remains unknown. In contrast, the data provided by Wright and coworkers now 
suggest a protective role for PGC-1 against high fat diet-induced insulin resistance in 
skeletal muscle. Similarly, the moderate and acute modulation of electroporated PGC-
1 in muscle resulted in improvement of insulin sensitivity in muscle of lean and 
obese Zucker rats [11]. Interestingly, the exact opposite observation, namely a more 
rapidly progressing insulin resistance, was observed in high fat-fed muscle-specific 
PGC-1 transgenic mice [12]. As in the study by Bonen and colleagues on PGC-1 
[11], the electroporation-based approach to increase PGC-1 levels in individual 
muscles used by Wright and coworkers differs from the muscle-specific transgenic 
animals with a stronger, chronic elevation of PGC-1 [13]. For example, potentially 
confounding effects due to the strong transgenic expression, such as the strong 
inhibition of PGC-1 gene expression in the PGC-1 muscle-specific transgenic 
animals [13] that could contribute to the muscle fiber-type switch observed in these 
mice, were not encountered by Wright et al. Thus, in combination with the previous 
work by Bonen and colleagues [11], Wright et al. propose that a moderate, acute 
elevation of PGC-1 or PGC-1, respectively, restores insulin sensitivity, at least in 
glycolytic muscles in rats. Accordingly, modulation of PGC-1 and PGC-1 gene 
expression might be an attractive novel therapeutic option against type 2 diabetes. 
However, pharmacological interventions aimed at the PGC-1 coactivators are not 
trivial to design [3]. First, chemical entities that selectively induce PGC-1 or PGC-
1 gene expression in skeletal muscle remain elusive. Second, pharmacological 
methods that alter PGC-1 levels must hit a therapeutically beneficial window in order 
to avoid the detrimental effects associated with inadequate or excessive PGC-1 
expression [3]. Finally, some paradoxical findings about the PGC-1 coactivators in 
muscle remain unexplained. For example, in the present study, PGC-1 expression 
and oxidative metabolism already increase as a consequence of the high fat diet and it 
is unclear how a further elevation of PGC-1 exerts the observed amelioration of 
insulin sensitivity. Moreover, while ectopic PGC-1 lowers the long chain acyl-CoA 
pool in muscle, the high fat diet-induced elevation of intramuscular ceramide and 
diacylglycerol, both strongly implicated in causing insulin resistance [5], is 
unaffected. It is also unclear how the chronic vs. acute and moderate vs. strong 
expression of PGC-1 and PGC-1 differ mechanistically and, at least in the case of 
PGC-1, result in diametrically opposite outcomes in terms of peripheral insulin 
sensitivity. Whether this is also true for PGC-1 is unclear since the effect of the 
transgenic expression of PGC-1 in muscle on insulin resistance has not been 
elucidated yet [13]. Therefore, more studies are needed to fundamentally understand 
the regulation and function of the PGC-1s in skeletal muscle before an appropriate 
drug targeting strategy aimed at these coactivators can be attempted. 
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Figure Legend 
 
Figure 1. Overexpression of PGC-1 in glycolytic rat skeletal muscles improves 
insulin sensitivity. a, A high fat diet promotes the increase in intramuscular levels of 
ceramide, diacylglycerol (DAG), long-chain acyl CoA entities (LCACoA) and 
reactive oxygen species (ROS), all of which contribute to the development of insulin 
resistance. The reason for the increase in mitochondrial function and PGC-1 
expression in muscle of high fat-fed rats remains unclear. It is conceivable that the 
resulting boost in fatty acid oxidation is an adaptive compensatory, yet inadequate 
mechanism to deal with the lipid overload. b, Ectopic expression of PGC-1 in 
electroporated glycolytic rat muscles results in increased mitochondrial function, fatty 
acid metabolism and antioxidant defense. As a consequence, LCACoA levels are 
lowered. Despite the inability of ectopic PGC-1 to reduce intramuscular ceramide 
and DAG, an improvement in insulin sensitivity is achieved. 
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